Dendritic cell-based immunotherapy is a promising strategy against cancer that appears to be feasible, safe and to induce potent tumor-specific immune responses. The use of naturally circulating dendritic cells (DCs), rather than cultured monocyte-derived DCs, might constitute the next logical step to translate anticancer immune responses into long-lasting clinical benefits.
No takes yet. Share an insight, caveat, or question.
Bol et al. (2013) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: